Analyst firms · Citigroup · EW
Citigroup EW price target and rating history
Edwards Lifesciences Corporation (EW) · Health Care
Citigroup rates Edwards Lifesciences Corporation (EW) Buy with a $105 price target, as of its latest action on May 22, 2024. It has published 4 rating actions on EW since December 2021, including 2 upgrades and 1 downgrade. Across 7 firms with a EW price target in the last 12 months, the median target is $110.
- Current rating
- Buy
- Price target
- $105
- Median target, all firms
- $110
- Actions on EW
- 4
Citigroup price target on EW
Every Citigroup rating on EW
- May 22, 2024
- Dec 11, 2023
- Jan 27, 2022
- Dec 15, 2021
How other firms rate EW
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Robert W. Baird | Outperform | $116 | Nov 5, 2026 |
| Truist Securities | Buy | $113 | Nov 4, 2026 |
| Barclays | Overweight | $110 | Oct 7, 2026 |
| UBS | Buy | $110 | Jul 28, 2026 |
| Leerink Partners | Outperform | $101 | Jul 24, 2026 |
| Wolfe Research | Outperform | $92 | Apr 1, 2026 |
| TD Cowen | Buy | $97 | Jan 9, 2026 |
Questions about Citigroup and EW
- What is Citigroup's price target for EW?
- Citigroup's latest stated price target for Edwards Lifesciences Corporation (EW) is $105, from its action on May 22, 2024.
- What is Citigroup's rating on EW?
- Citigroup rates EW Buy, a bullish rating, as of May 22, 2024.
- When did Citigroup last change its view on EW?
- On May 22, 2024, Citigroup upgrades to Buy from Neutral, price target $98 to $105.
- How does Citigroup's EW target compare with other analysts?
- Across 7 firms with a EW price target in the last 12 months, the median target is $110.
More EW rating histories
- Robert W. Baird3
- Truist Securities3
- UBS5
- Leerink Partners6
- Wolfe Research6
- Raymond James6
- Jefferies4
- Oppenheimer4
- Evercore ISI3
- Piper Sandler4
- Stifel4
- BofA Securities4
- Morgan Stanley6
- Wells Fargo6
- Credit Suisse3
All Citigroup ratingsEW news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.